Dreaming Big and Thinking Small: Applying Medicinal Chemistry Strategy to Antibody-Drug-Conjugates
June 23, 2016
Session 6 of the 2016 Drug Design and Delivery Symposium
Antibody-Drug-Conjugates (ADCs) serve as targeted delivery vehicles for small molecule therapeutic agents. While at first glance the development of an ADC and a small molecule therapeutic may seem very different, L. Nathan Tumey will provide an overview of how medicinal chemistry strategies can be applied to optimize the efficacy and stability of ADCs. He will illustrate how our understanding of ADC design is growing by using several case studies involving various Pfizer ADC programs.
*Access to this recording is an exclusive benefit for ACS Members.
What You Will Learn
- How principles of small molecule medicinal chemistry can be applied towards ADC programs
- The importance of bioanalytical tools for the characterization of ADCs
- Ways that site-specific conjugation can solve metabolic problems
Additional Resources
The Fine Print
ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.
Experts
L. Nathan Tumey
Pfizer
Peter Senter
Seattle Genetics, Inc.
Co-Produced By
;void(0);){kind=link}